Company Name: |
Nuvectis Pharma Inc |
Sector: |
Biotechnology |
Nuvectis Pharma is a biopharmaceutical company focused on the development of medicines for the treatment of medical needs in oncology. Co. uses target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Co. is developing two preclinical drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 pathway. NXP800 targets ovarian clear cell carcinoma and endometrioid ovarian cancer. NXP900 is an oral small molecule designed to inhibit the SRC and YES1 kinases. NXP900 is in preclinical development with IND-enabling studies. The median 12 month forward target price among analysts covering NVCT is $21.0/share.